#### Check for updates

#### **OPEN ACCESS**

EDITED BY Francesk Mulita, General University Hospital of Patras, Greece

#### REVIEWED BY

Christos Pitros, General University Hospital of Patras, Greece Georgios-Ioannis Verras, Epsom and St Helier University Hospitals NHS Trust, United Kingdom Fotios Iliopoulos, General University Hospital of Patras, Greece

\*CORRESPONDENCE Guo-le Lin Inguole@126.com

RECEIVED 01 November 2023 ACCEPTED 29 November 2023 PUBLISHED 15 December 2023

#### CITATION

Li G-b, Qiu X-y, Zhang X, Zhang N and Lin G-l (2023) Case report: The application of neoadjuvant chemoradiotherapy in anal adenocarcinoma combined with perianal Paget disease involving vulvar skin. *Front. Oncol.* 13:1327173. doi: 10.3389/fonc.2023.1327173

#### COPYRIGHT

© 2023 Li, Qiu, Zhang, Zhang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Case report: The application of neoadjuvant chemoradiotherapy in anal adenocarcinoma combined with perianal Paget disease involving vulvar skin

Gan-bin Li, Xiao-yuan Qiu, Xiao Zhang, Ning Zhang and Guo-le Lin\*

Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China

Anal adenocarcinoma combined with perianal Paget's disease (PPD) involving the vulva is rare, and there is no established standard treatment. We present the case of a 69-year-old woman with symptoms of intermittent hematochezia and perianal discomfort for 7 months. Upon examination, we discovered a plaque-like hard mass on the right posterior wall of the anal canal, which extended to encompass the anus and dentate line. The lesion skin also extended forward from the gluteal groove, involving the bilateral labial area. Colonoscopy revealed an extensive protruding lesion on the dentate line, which was confirmed as anal adenocarcinoma (mrT4N0M0). The presence of Paget's cells in perianal and vulvar skins led to the diagnosis of PPD. The strategy of neoadjuvant chemoradiotherapy (nCRT) followed by radical surgery was then made after multi-disciplinary discuss. The scope and extent of perianal and vulvar disease were significantly diminished after nCRT. The patient underwent laparoscopic abdominoperineal resection and vulvar lesion resection, confirming the diagnosis of anal adenocarcinoma (ypT2N0). No evidence of tumor cells was found in perianal and vulvar skin, indicating a complete response. The patient is regularly monitored without recurrence or metastasis.

#### KEYWORDS

anus neoplasms, Paget disease, extramammary, neoadjuvant therapy, efficacy, case report

# Introduction

Paget disease is characterized by adenocarcinoma localized within the epidermis of the nipple or areola of the breast (1). Extramammary Paget disease (EMPD) is a relatively rare malignancy developed on apocrine-rich skin, such as the vulva, scrotum, and penis, with a reported incidence of 0.1-2.4 patients per 1,000,000 person-years (2, 3). EMPD predominantly presents as a slowly enlarging asymmetrical erythematous plaque, and pruritus is a common symptom (4). The mechanism underlying EMPD develop remain unclear; however, a popular theory posits that primary EMPD arises as an intraepidermal neoplasm originating from the cells of the apocrine gland ducts (5). Owing to its nonspecific clinical presentation and insidious onset, EMPD is often misdiagnosed, resulting in delayed treatment (6).

Perianal Paget disease (PPD) develops near the anus, but in rare cases (~20% of EMPD lesions) can spread across the perineum, genitalia, gluteal canal, and anal canal (7). The perianal region is the second most common site, with 5% of all EMPD lesions originating from the anorectal region (1, 7, 8). The standard-of-care management strategy for PPD is comprehensive, including radiotherapy, local excision, and radical surgery; however, no consensus exists regarding the superiority of local excision and radical surgery, especially in cases of accompanied anal adenocarcinoma (9). Here, we report a rare case of an anal tumor combined with PPD involving the vulvar skin with extensive and massive lesions. Based on our experience with the management of rectal cancer, we decided to apply neoadjuvant chemoradiotherapy (nCRT) followed by radical surgical resection, achieving a satisfactory outcome.

# Case presentation

### Complaints and colonoscopy

The overall treatment procedure is illustrated in Figure 1. A 69year woman was admitted to our hospital complaining of intermittent hematochezia and perianal discomfort for 7 months. The patient had initially developed intermittent hematochezia, characterized by dark bloody stool, accompanied by perianal pruritus and pain 7 months prior. Upon examination, pigmentation of the local skin and chapped epidermal hyperplasia, as well as a plaque-like hard mass, were found on the right posterior wall of the anal canal, involving the anus and dentate line. The patient's primary manifestations were changes in defecation habits, including diarrhea and a feeling of urgency during defecation (Figure 2A). The aforementioned painful symptoms led the patient to visit the hospital for further examination. A digital colonoscopy (July 14, 2022) revealed an extensive protrudent lesion on the dentate line, and the biopsy results revealed moderately differentiated adenocarcinoma in the anal canal, while papillomatous hyperplasia was characterized by scattered glandular distributed heteromorphic cells with abundant cytoplasm at the lesions around the perianal and vulvar skins, meeting the features of Paget's cells (Figures 3A-C).

### Rectal MRI examination

The patient's typical pathologic features led us to consider the diagnosis of PPD (Figure 3D). There were no metastatic lesions in



resonance imaging; MDT, Multi-disciplinary treatment; CR, Complete response



#### FIGURE 2

Physical examination. The scope of lesions were marked in yellow dotted line, the most typical lesion was marked in yellow arrow. (A) The overall outlook of perianal disease, an obvious mass protruding out of anal canal before nCRT; (B) The massive scope of vulva lesions, and the lesion skin before nCRT; (C) The overall outlook of perianal region after nCRT; (D) the lesions of vulvar region with no macroscopic lesions after nCRT; (E) Anterior view of the excised specimen; (F) The image of the dissected specimen; (G) Images after surgery; (H) Perineal incision on postoperative day 9. nCRT, neoadjuvant chemoradiotherapy.

the liver or lungs, and tumor markers were normal. An irregular mass protruding into the intestinal cavity was observed from the 6 to 12 o' clock positions in the entire section of the anal canal, detected by rectal MRI. The maximum section was 4.0 cm \* 2.0 cm.

The lesion protruded from the external anal margin, the involved anal canal became stenotic. The anterior edge of the lesion involved the posterior wall of the vagina and was staged as mrT4N0M0 (Figures 4A–C).



#### FIGURE 3

The results of colonoscopy and pathology. (A) Anus lesion, protrusion and nodular lesions at anal canal and perianal mucosa, the most typical lesion was marked in yellow arrow; (B) The lesions at perianal region; (C) The proximal mucosa was normal; (D) Pathology of biopsied perianal skin before nCRT, Paget's like tumor cells could be found, marked in yellow arrow. (E) Pathologic result of anal adenocarcinoma; (F) Pathologic result of resected perianal and vulva lesions. nCRT, neoadjuvant chemoradiotherapy.



#### FIGURE 4

The typical images of anal adenocarcinoma before and after nCRT in three dimensions. The lesions were marked in yellow arrow. (A) The axial images before nCRT, the irregular mass protruding into the intestinal cavity; (B) The sagittal images before nCRT; (C) Lesions presented by DWI before nCRT; (D) The axial images after nCRT; (E, F) represent the sagittal and DWI lesions after nCRT. nCRT, neoadjuvant chemoradiotherapy; DWI, Diffusion weighted imaging; TRG, Tumor regression grade.

Physical examination revealed that local skin pigmentation and chapped epidermic hyperplasia could be found on the right side of the anus with a range  $2.0 \times 3.0$  cm in scope, while a plaque-like hard mass (~1.5 cm in diameter) was observed on the right posterior wall of the anal canal, involving the anus and dentate line. The lesion skin developed from the gluteal groove forward involving the bilateral area of the labia (Figures 2A, B).

### Multi-disciplinary discussion

Considering that diagnosis of anal adenocarcinoma combined with PPD involving the vulvar skin, we organized a multidisciplinary panel to determine the optimal strategies. The dermatologist consulted the pathological sections of the perianal skin again, which showed heterotypic epithelial cells visible in the basal layer and epidermis, accompanied by a slightly stained cytoplasm. PPD was considered firstly when combined with immunohistochemical results (positive for CK7/CK20/CEA/PAS). In addition, the scope of the vulvar lesions was determined using fluorescence diagnostic technology and biopsy, which revealed that the epidermal spinous layer was hypertrophic, with a large number of Paget-like cells with obvious atypia. The gynecologist held the view that the chapped and depigmented skin lesions developed from the perianal area to the bilateral regions of the labia, radical surgery was difficult. Although the diagnosis was clear, the oncologist believed that the lesions involved a large area and that direct surgery might be difficult, and neoadjuvant radiotherapy concurrent with capecitabine might therefore be the optimal choice.

The plastic surgeon was recruited to assist in the removal and repair of soft tissue lesions, if necessary.

### NCRT and subsequent re-evaluation

A strategy was chosen to administer nCRT followed by radical surgery. The patient received 25 fractions of radiotherapy, followed by 2 cycles of oral capecitabine between October 4, 2022, and November 8, 2022. The treatment course was welltolerated without any notable discomfort (Figure 1).

Re-evaluation by MRI revealed an irregular mass protruding into the cavity of the anal canal. The maximum cross section was about 1.3 cm  $\times$  2.2 cm, the solid component of tumor mass was significantly reduced, and mucus signals were visible in the anal canal. The application of nCRT effectively reduced both the volume and diameter of the tumor mass to an extremely diminished status, with MRI indicating a tumor regression grade reaching TRG 3 (Figures 4D–F).

Physical examination revealed scattered erythematous changes on the perianal skin, although no eminent lesions observed on the perianal skin. Digital rectal examination (thoraco-knee position) revealed a hard mass on the right posterior wall of the anal canal under the dentate line, which was significantly decreased compared with the pre-neoadjuvant period; lesions on the bilateral labia were also significantly improved, with no obvious pigmentation or chapped skin (Figures 2C, D).

### Surgery and follow-up

The patient was subsequently scheduled for laparoscopic abdominoperineal resection combined with vulvar lesion resection on February 3, 2023, the resected specimens of anal tumor along with perianal lesions were displayed in Figures 2E, F. The surgery was successful, and the patient was discharged from the hospital on postoperative day 10 (Figures 2G, H). Pathological review of the resected specimens revealed that the anal mass was a moderately differentiated adenocarcinoma staged as ypT2N0, and the tumor regression grade was reaching CAP 2 (Figure 3E), there was no evidence of tumor cells in the resected perianal and vulvar lesions (Figure 3F), Immunohistochemistry indicated positivity for CK20 (+), CDX-2 (+), MUC2 (+), GCDFP-15 (+), and negative CK-7. Follow-up is currently ongoing, and no evidence of recurrence or metastasis has been observed.

## Discussion

EMPD is a malignancy originating from epithelial cells, which is predominantly distributed in the perineum, external genitalia, and other apocrine-rich sites. These lesions are generally confined to the epidermis, dermis, or subcutaneous soft tissue, later transforming into invasive lesions through recurrence and metastasis (8). EMPD is mostly a single-organ disease, and only 4% of cases are complicated by multiple lesions (10).

The incidence of EMPD is low, and its clinical manifestations lack specificity, mainly presenting as erythema, erosion, ulcers and hyperpigmentation (8). Multi-point full-layer puncture is an important diagnostic method for EMPD. In EMPD, single cells or clusters of Paget cells can be arranged in the epidermis, dermis, or subcutaneous tissues. Paget cells are larger than keratinocytes, and their cytoplasm is more pale or granular (11). Immunohistochemistry also contributes to EMPD diagnosis. Positivity for keratin CK7/CK20 and CEA and negativity for SOX10 are suggestive of EMPD, whereas positivity for CK20 and CDX2 suggests the possibility of secondary EMPD (12, 13). In addition, site-specific tumor markers are also helpful for differential diagnosis, such as positivity for GCDFP15, indicating the origin of the genital system, and positivity for CDX2 and CK20, which may refer to perianal lesions, as presented in this case (14). Ultrasonography, colonoscopy, magnetic resonance imaging (MRI), computed tomography (CT), and other examinations can clarify and differentiate between the diagnosis (1, 8, 11).

Radical surgery is a vital treatment for primary EMPD, and the essential principle is to ensure that all surgical margins are negative. Local or extended local resection or Mohs minimally invasive surgery can also be performed; however, the postoperative recurrence rate can reach as high as 30% (13). Conservative treatment or local radiotherapy can also be used as alternative treatments. Adjuvant chemotherapy, targeted therapy, and immunotherapy may also be used to manage metastatic EMPD (15). For secondary EMPD, a multidisciplinary collaboration is required to develop precise treatment plans.

Whether nCRT can be applied in the treatment of invasive PPD, particularly when accompanied by simultaneous anal canal adenocarcinoma, remains controversial (2, 16). In this case, anal adenocarcinoma was combined with PPD that invaded the vulva, and the lesions were diffuse and involved a large area between the perianus and labia. If surgical resection is chosen for the first time, combined abdominoperineal resection and extended resection of the vulva may be mandatory, which is extensive and traumatic; further, flap transplantation and vulvar reconstruction may also be required for radical purpose (17). After a multidisciplinary consultation, we decided to gain experience with the comprehensive treatment of midto-low locally advanced rectal cancer using neoadjuvant long-course radiotherapy, followed by concurrent single-agent oral capecitabine for a total of two cycles.

This study has certain limitations. Firstly, in the process of assessing the treatment efficacy after neoadjuvant chemoradiotherapy, there was no subsequent biopsy of the perianal skin and the lesion site in the perineum. Confirming complete remission of perianal and perineal lesions before surgery could have further reduced the extent of the surgical procedure. Additionally, this study only reports one-year postoperative survival outcomes, which represents a relatively short follow-up period. Long-term survival prognosis for patients should be tracked more extensively in the future.

The application of nCRT has two purposes: first, the sizes and scope of lesions can be reduced, in some cases even achieving complete clinical response; second, it can achieve a reduction in tumor size and stage through chemoradiotherapy, as well as increasing tumor local control and eradication of micrometastasis to reduce the possibility of local recurrence and distant metastasis (16, 18). In the present patient, after nCRT, the lesions in the perianal region were significantly reduced, no clear swelling lesions were found around the anus after treatment, and the scope of vulvar lesions was also diminished compared to that before treatment (18). Postoperative pathological results confirmed that after nCRT, no tumor cells could be found around the anus and vulva, and the overall treatment effect was promising. During surgery, radical resection was ensured by repeated inspection of the incisal margin. The resection scope of vulvar lesions was relatively limited, and a one-stage suture was feasible, avoiding flap transplantation and vulvar reconstruction.

# Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

# **Ethics statement**

The studies involving humans were approved by the Ethics Committee of Peking Union Medical College Hospital (No. JS-1296). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

# Author contributions

GL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Visualization, Writing – original draft. XQ: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Writing – review & editing. XZ: Conceptualization, Data curation, Formal analysis, Methodology, Resources, Writing – review & editing. NZ: Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Writing – review & editing. GL: Funding acquisition, Investigation, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing – review & editing.

# References

1. Morris CR, Hurst EA. Extramammary paget disease: A review of the literature: history, epidemiology, pathogenesis, presentation, histopathology, and diagnostic work-up. *Dermatol Surg* (2020) 46(2):151–8. doi: 10.1097/DSS.000000000002064

2. Herrel LA, Weiss AD, Goodman M, Johnson TV, Osunkoya AO, Delman KA, et al. Extramammary Paget's disease in males: survival outcomes in 495 patients. *Ann Surg Oncol* (2015) 22(5):1625–30. doi: 10.1245/s10434-014-4139-y

3. Siesling S, Elferink MA, van Dijck JA, Pierie JP, Blokx WA. Epidemiology and treatment of extramammary Paget disease in the Netherlands. *Eur J Surg Oncol* (2007) 33(8):951–5. doi: 10.1016/j.ejso.2006.11.028

4. Hatta N, Yamada M, Hirano T, Fujimoto A, Morita R. Extramammary Paget's disease: treatment, prognostic factors and outcome in 76 patients. *Br J Dermatol* (2008) 158(2):313–8. doi: 10.1111/j.1365-2133.2007.08314.x

5. Schaapveld M, Visser O, Louwman MJ, de Vries EG, Willemse PH, Otter R, et al. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study. *J Clin Oncol* (2008) 26(8):1239–46. doi: 10.1200/JCO.2007.11.9081

6. Funaro D, Krasny M, Lam C, Desy D, Sauthier P, Bouffard D. Extramammary Paget disease: epidemiology and association to cancer in a Quebec-based population. *J Low Genit Tract Dis* (2013) 17(2):167–74. doi: 10.1097/LGT.0b013e31825f4b4f

7. Williams SL, Rogers LW, Quan SH. Perianal Paget's disease: report of seven cases. Dis Colon Rectum (1976) . 19(1):30–40. doi: 10.1007/BF02590848

8. Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Downing MB, et al. Evidence-based clinical practice guidelines for extramammary Paget disease. *JAMA Oncol* (2022) 8(4):618–28. doi: 10.1001/jamaoncol.2021.7148

9. Luyten A, Sörgel P, Clad A, Gieseking F, Maass-Poppenhusen K, Lellé RJ, et al. Treatment of Extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy Network. *J Am Acad Dermatol* (2014) 70(4):644–50. doi: 10.1016/j.jaad.2013.12.008

10. Yélamos O, Hibler BP, Cordova M, Hollmann TJ, Kose K, Marchetti MA, et al. Handheld reflectance confocal microscopy for the detection of recurrent

# Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Supported by the National High Level Hospital Clinical Research Funding (No. 2022-PUMCH-C-005).

# Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Extramammary Paget disease. *JAMA Dermatol* (2017) 153(7):689–93. doi: 10.1001/jamadermatol.2017.0619

11. Navarrete-Dechent C, Aleissa S, Cordova M, Hibler BP, Erlendsson AM, Polansky M, et al. Treatment of extramammary Paget disease and the role of reflectance confocal microscopy: A prospective study. *Dermatol Surg* (2021) 47 (4):473–9. doi: 10.1097/DSS.00000000002934

12. Pan ZY, Liang J, Zhang QA, Lin JR, Zheng ZZ. *In vivo* reflectance confocal microscopy of extramammary Paget disease: diagnostic evaluation and surgical management. *J Am Acad Dermatol* (2012) 66(2):e47-53. doi: 10.1016/j.jaad.2010.09.722

13. Bayan CY, Khanna T, Rotemberg V, Samie FH, Zeitouni NC. A review of noninvasive imaging in extramammary Paget's disease. J Eur Acad Dermatol Venereol (2018) 32(11):1862–73. doi: 10.1111/jdv.15072

14. Kawaguchi M, Kato H, Noda Y, Kobayashi K, Miyazaki T, Hyodo F, et al. Imaging findings of Malignant skin tumors: radiological-pathological correlation. *Insights Imaging* (2022) 13(1):52. doi: 10.1186/s13244-022-01205-8

15. Appert DL, Otley CC, Phillips PK, Roenigk RK. Role of multiple scouting biopsies before Mohs micrographic surgery for extramammary Paget's disease. *Dermatol Surg* (2005) 31(11):1417-22. doi: 10.2310/6350.2005.31207

16. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. NCCN guidelines insights: rectal cancer, version 6.2020. *J Natl Compr Canc Netw* (2020) 8(7):806–15. doi: 10.6004/jnccn.2020.0032

17. Karam A, Dorigo O. Treatment outcomes in a large cohort of patients with invasive Extramammary Paget's disease. *Gynecol Oncol* (2012) 125(2):346–51. doi: 10.1016/j.ygyno.2012.01.032

18. Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. *Ann Oncol* (2013) 24(3):718–25. doi: 10.1093/annonc/mds519